Cytoplasmic prion protein induces forebrain neurotoxicity

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 6, 2009, Pages 555-563

  Wang, Xinhe ^a   Bowers, Stephanie L ^a   Wang, Fei ^a   Pu, Xin an ^a   Nelson, Randy J ^a   Ma, Jiyan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Forebrain neurotoxicity; Membrane perturbation; Oligomer; Prion; PrP

Indexed keywords

CYTOPLASM PROTEIN; OLIGOMER; PRION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOSIS; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN NERVE CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXPERIMENTAL TEST; FOREBRAIN; GENE DOSAGE; HIPPOCAMPUS; HISTOPATHOLOGY; HYPERACTIVITY; IMMUNOBLOTTING; MOUSE; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; CYTOPLASM; HIPPOCAMPUS; HOMOZYGOTE; LIPID BILAYERS; MICE; MICE, TRANSGENIC; NEURONS; NEUROTOXICITY SYNDROMES; PRION DISEASES; PROSENCEPHALON; PRPC PROTEINS;

MUS; MUS MUSCULUS;

EID: 67349103903     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.02.014     Document Type: Article

References (52)

1. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13363-13383
2. Aguzzi A., Sigurdson C., and Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu. Rev. Pathol. 3 (2008) 11-40
3. Caughey B., and Baron G.S. Prions and their partners in crime. Nature 443 (2006) 803-810
4. Collinge J., and Clarke A.R. A general model of prion strains and their pathogenicity. Science 318 (2007) 930-936
5. Bueler H., Aguzzi A., Sailer A., Greiner R.A., Autenried P., Aguet M., and Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 73 (1993) 1339-1347
6. Brandner S., Isenmann S., Raeber A., Fischer M., Sailer A., Kobayashi Y., Marino S., Weissmann C., and Aguzzi A. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379 (1996) 339-343
7. Mallucci G., Dickinson A., Linehan J., Klohn P.C., Brandner S., and Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302 (2003) 871-874
8. Mironov Jr. A., Latawiec D., Wille H., Bouzamondo-Bernstein E., Legname G., Williamson R.A., Burton D., DeArmond S.J., Prusiner S.B., and Peters P.J. Cytosolic prion protein in neurons. J. Neurosci. 23 (2003) 7183-7193
9. Jin T., Gu Y., Zanusso G., Sy M., Kumar A., Cohen M., Gambetti P., and Singh N. The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J. Biol. Chem. 275 (2000) 38699-38704
10. Yedidia Y., Horonchik L., Tzaban S., Yanai A., and Taraboulos A. Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J. 20 (2001) 5383-5391
11. Ma J., and Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14955-14960
12. Rane N.S., Yonkovich J.L., and Hegde R.S. Protection from cytosolic prion protein toxicity by modulation of protein translocation. EMBO J. 23 (2004) 4550-4559
13. Kang S.W., Rane N.S., Kim S.J., Garrison J.L., Taunton J., and Hegde R.S. Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway. Cell 127 (2006) 999-1013
14. Rane N.S., Kang S.W., Chakrabarti O., Feigenbaum L., and Hegde R.S. Reduced translocation of nascent prion protein during ER stress contributes to neurodegeneration. Dev. Cell 15 (2008) 359-370
15. Ma J., Wollmann R., and Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298 (2002) 1781-1785
16. Rambold A.S., Miesbauer M., Rapaport D., Bartke T., Baier M., Winklhofer K.F., and Tatzelt J. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol. Biol. Cell 17 (2006) 3356-3368
17. Grenier C., Bissonnette C., Volkov L., and Roucou X. Molecular morphology and toxicity of cytoplasmic prion protein aggregates in neuronal and non-neuronal cells. J. Neurochem. 97 (2006) 1456-1466
18. Fioriti L., Dossena S., Stewart L.R., Stewart R.S., Harris D.A., Forloni G., and Chiesa R. Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations. J. Biol. Chem. 280 (2005) 11320-11328
19. Crozet C., Vezilier J., Delfieu V., Nishimura T., Onodera T., Casanova D., Lehmann S., and Beranger F. The truncated 23-230 form of the prion protein localizes to the nuclei of inducible cell lines independently of its nuclear localization signals and is not cytotoxic. Mol. Cell. Neurosci. 32 (2006) 315-323
20. Roucou X., Guo Q., Zhang Y., Goodyer C.G., and LeBlanc A.C. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 278 (2003) 40877-40881
21. Jodoin J., Laroche-Pierre S., Goodyer C.G., and LeBlanc A.C. Defective retrotranslocation causes loss of anti-Bax function in human familial prion protein mutants. J. Neurosci. 27 (2007) 5081-5091
22. Montagna P., Gambetti P., Cortelli P., and Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2 (2003) 167-176
23. Gambetti P., Kong Q., Zou W., Parchi P., and Chen S.G. Sporadic and familial CJD: classification and characterisation. Br. Med. Bull. 66 (2003) 213-239
24. Collins S., McLean C.A., and Masters C.L. Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J. Clin. Neurosci. 8 (2001) 387-397
25. Kovacs G.G., Trabattoni G., Hainfellner J.A., Ironside J.W., Knight R.S., and Budka H. Mutations of the prion protein gene phenotypic spectrum. J. Neurol. 249 (2002) 1567-1582
26. Mansuy I.M., Winder D.G., Moallem T.M., Osman M., Mayford M., Hawkins R.D., and Kandel E.R. Inducible and reversible gene expression with the rtTA system for the study of memory. Neuron 21 (1998) 257-265
27. Young K.A., Berry M.L., Mahaffey C.L., Saionz J.R., Hawes N.L., Chang B., Zheng Q.Y., Smith R.S., Bronson R.T., Nelson R.J., and Simpson E.M. Fierce: a new mouse deletion of Nr2e1; violent behaviour and ocular abnormalities are background-dependent. Behav. Brain Res. 132 (2002) 145-158
28. Wang X., Wang F., Arterburn L., Wollmann R., and Ma J. The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity. J. Biol. Chem. 281 (2006) 13559-13565
29. Wang F., Yang F., Hu Y., Wang X., Jin C., and Ma J. Lipid interaction converts prion protein to a PrPSc-like proteinase K-resistant conformation under physiological conditions. Biochemistry 46 (2007) 7045-7053
30. Nishiyama A., Endo T., Takeda S., and Imamura M. Identification and characterization of epsilon-sarcoglycans in the central nervous system. Brain Res. Mol. Brain Res. 125 (2004) 1-12
31. Yin S., Pham N., Yu S., Li C., Wong P., Chang B., Kang S.C., Biasini E., Tien P., Harris D.A., and Sy M.S. Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 7546-7551
32. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., and Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
33. Dunah A.W., and Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21 (2001) 5546-5558
34. Onofri F., Giovedi S., Vaccaro P., Czernik A.J., Valtorta F., De Camilli P., Greengard P., and Benfenati F. Synapsin I interacts with c-Src and stimulates its tyrosine kinase activity. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12168-12173
35. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
36. Shorter J., and Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304 (2004) 1793-1797
37. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279 (2004) 46363-46366
38. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., and Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280 (2005) 17294-17300
39. Polymenidou M., Stoeck K., Glatzel M., Vey M., Bellon A., and Aguzzi A. Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease. Lancet Neurol. 4 (2005) 805-814
40. Chandrasekaran K., Hazelton J.L., Wang Y., Fiskum G., and Kristian T. Neuron-specific conditional expression of a mitochondrially targeted fluorescent protein in mice. J. Neurosci. 26 (2006) 13123-13127
41. Steele A.D., Hetz C.H., Yi C.H., Jackson W.S., Borkowski A.W., Yuan J., Wollmann R.H., and Lindquist S. Prion pathogenesis is independent of caspase-12. Prion 1 (2007) 1-5
42. Steele A.D., King O.D., Jackson W.S., Hetz C.A., Borkowski A.W., Thielen P., Wollmann R., and Lindquist S. Diminishing apoptosis by deletion of Bax or overexpression of Bcl-2 does not protect against infectious prion toxicity in vivo. J. Neurosci. 27 (2007) 13022-13027
43. Coulpier M., Messiaen S., Hamel R., Fernandez de Marco M., Lilin T., and Eloit M. Bax deletion does not protect neurons from BSE-induced death. Neurobiol. Dis. 23 (2006) 603-611
44. Mishra R.S., Bose S., Gu Y., Li R., and Singh N. Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders. J. Alzheimers Dis. 5 (2003) 15-23
45. Zanusso G., Petersen R.B., Jin T., Jing Y., Kanoush R., Ferrari S., Gambetti P., and Singh N. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J. Biol. Chem. 274 (1999) 23396-23404
46. Yamada M., Itoh Y., Inaba A., Wada Y., Takashima M., Satoh S., Kamata T., Okeda R., Kayano T., Suematsu N., Kitamoto T., Otomo E., Matsushita M., and Mizusawa H. An inherited prion disease with a PrP P105L mutation: clinicopathologic and PrP heterogeneity. Neurology 53 (1999) 181-188
47. Hsiao K.K., Scott M., Foster D., Groth D.F., DeArmond S.J., and Prusiner S.B. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. [see comments]. Science 250 (1990) 1587-1590
48. Chiesa R., Piccardo P., Ghetti B., and Harris D.A. Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. Neuron 21 (1998) 1339-1351
49. Nazor K.E., Kuhn F., Seward T., Green M., Zwald D., Purro M., Schmid J., Biffiger K., Power A.M., Oesch B., Raeber A.J., and Telling G.C. Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. EMBO J. 24 (2005) 2472-2480
50. Kristiansen M., Deriziotis P., Dimcheff D.E., Jackson G.S., Ovaa H., Naumann H., Clarke A.R., van Leeuwen F.W., Menendez-Benito V., Dantuma N.P., Portis J.L., Collinge J., and Tabrizi S.J. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell 26 (2007) 175-188
51. Jerecic J., Single F., Kruth U., Krestel H., Kolhekar R., Storck T., Kask K., Higuchi M., Sprengel R., and Seeburg P.H. Studies on conditional gene expression in the brain. Ann. N. Y. Acad. Sci. 868 (1999) 27-37
52. Wang X., Wang F., Sy M.S., and Ma J. Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol. J. Biol. Chem. 280 (2005) 317-325